<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556021</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_302</org_study_id>
    <nct_id>NCT02556021</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once
      daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, randomized, placebo-controlled, phase 3 study. Subjects will be
      randomly assigned to one of the three treatment groups (CJ-12420 50 mg or 100 mg or placebo).

      All subjects will be asked to take two tablets at the same time each day throughout the
      study, and also all subjects will be asked to record daily symptom in a subject diary on a
      daily basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 22, 2015</start_date>
  <completion_date type="Actual">November 1, 2016</completion_date>
  <primary_completion_date type="Actual">November 1, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with complete resolution of main symptoms (heartburn and regurgitation) at 4-week, defined as no episodes of symptom during the last 7 days of treatment, using Reflux Disease Questionnaire(RDQ)</measure>
    <time_frame>4 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of main symptoms(heartburn and regurgitation) at 2-week(for 7 consecutive days)</measure>
    <time_frame>2 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDQ score change</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of symptom free days</measure>
    <time_frame>4 week</time_frame>
    <description>Symptom will be collected by patient diary.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Non-erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>CJ-12420 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, tablet, once daily, oral administration for up to 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 50mg</intervention_name>
    <description>CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks</description>
    <arm_group_label>CJ-12420 50mg</arm_group_label>
    <other_name>Not yet decided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 100mg</intervention_name>
    <description>CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks</description>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <other_name>Not yet decided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, tablet, once daily, oral administration for up to 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 20 and 75 years

          2. Subjects who had experienced a minimum three-month history of main symptom(heartburn
             and regurgitation)

          3. Subjects were to have normal esophagus confirmed by endoscopy within 14 days prior to
             randomization

          4. Subjects who is able to understand and follow the instructions and is willing to
             participate throughout the entire study

          5. Subjects who voluntarily signed written informed consent form

          6. Subjects who agreed to use medically acceptable contraceptives during the period of
             study

          7. Subjects who had experienced heartburn and regurgitation within 7 days before
             randomization. Entry into study also required that patients had experienced at least
             mild upper gastrointestinal symptoms on at least 2 days/week or at least moderate
             upper gastrointestinal symptoms on at least 1 day/week

        Exclusion Criteria:

          1. Subjects who cannot undergo EGD

          2. Subjects who have esophageal stenosis, ulcer stenosis, gastroesophageal varices,
             Barrett's esophagus, active gastric ulcer, gastrointestinal bleeding or malignant
             tumor confirmed by EGD

          3. Subjects who have erosive esophagitis, acute upper gastrointestinal bleeding, gastric
             ulcers or duodenal ulcers, acute erosive gastritis within 2 months before
             randomization. Subjects with gastric or duodenal erosions are allowed to be included.

          4. Subjects who have warning symptoms of malignant gastrointestinal tract such as
             odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool

          5. Subjects with eosinophilic esophagitis

          6. Subjects diagnosed with functional dyspepsia, primary esophageal motility disorder,
             IBS, IBD, etc. or with suspected IBS in the last 3 months

          7. Subjects who have a history of gastric acid suppression surgery or upper
             gastrointestinal, esophageal surgery

          8. Subjects who have bipolar disorder, anxiety disorder, panic disorder, somatoform
             disorder, personality disorder and psychiatric disorders.

          9. Subjects who are taking antipsychotic drugs, antidepressants or antianxiety
             medications

         10. Subjects who should continuously administer NSAIDs during the trial.

         11. Pregnant or lactating women

         12. Subjects with a history of clinically significant hepatic, renal, cardiovascular,
             respiratory, endocrine and CNS system disorder

         13. Subjects with a history of hypersensitivity to the active ingredient or excipients of
             the study drug, etc.

         14. Subjects who participated in the other clinical trial within 4 weeks prior to
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yeouido St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

